Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review
详细信息 查看全文
- 作者：Jeremy Lewin (1)
Samantha Wieringa (2)
Marnie Collins (1)
Jayesh Desai (1)
Lisa Orme (1)
Senthil Lingaratnam (2)
David M Thomas (1) - 关键词：Ewing’s sarcoma ; Dose escalation ; Toxicity ; Neutropenia ; Chemotherapy
- 刊名：Clinical Sarcoma Research
- 出版年：2013
- 出版时间：November 2013
- 年：2013
- 卷：3
- 期：1
- 全文大小：270 KB
- 参考文献：1. Nesbit ME: class="a-plus-plus">Ewing’s sarcoma. / CA Cancer J Clin 1976, class="a-plus-plus">26:174-80. class="external" href="http://dx.doi.org/10.3322/canjclin.26.3.174" target="_blank" title="It opens in new window">CrossRef
2. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, / et al.: class="a-plus-plus">Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. / N Engl J Med 2003, class="a-plus-plus">348:694-01. class="external" href="http://dx.doi.org/10.1056/NEJMoa020890" target="_blank" title="It opens in new window">CrossRef
3. Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I: class="a-plus-plus">Ifosfamide-containing chemotherapy in Ewing’s sarcoma: the second united kingdom children’s cancer study group and the medical research council Ewing’s tumor study. / J Clin Oncol 1998, class="a-plus-plus">16:3628-633.
4. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, / et al.: class="a-plus-plus">Localized ewing tumor of bone: final results of the cooperative Ewing’s sarcoma study CESS 86. / J Clin Oncol 2001, class="a-plus-plus">19:1818-829.
5. Balamuth NJ, Womer RB: class="a-plus-plus">Ewing’s sarcoma. / Lancet Oncol 2010, class="a-plus-plus">11:184-92. class="external" href="http://dx.doi.org/10.1016/S1470-2045(09)70286-4" target="_blank" title="It opens in new window">CrossRef
6. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, / et al.: class="a-plus-plus">Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. / J Clin Oncol 2003, class="a-plus-plus">21:3423-430. class="external" href="http://dx.doi.org/10.1200/JCO.2003.10.033" target="_blank" title="It opens in new window">CrossRef
7. Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P, / et al.: class="a-plus-plus">Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. / J Clin Oncol 1990, class="a-plus-plus">8:1514-524.
8. Bleyer A, Choi M, Fuller CD, Thomas CR Jr, Wang SJ: class="a-plus-plus">Relative lack of conditional survival improvement in young adults with cancer. / Semin Oncol 2009, class="a-plus-plus">36:460-67. class="external" href="http://dx.doi.org/10.1053/j.seminoncol.2009.07.004" target="_blank" title="It opens in new window">CrossRef
9. Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kuhne T, Sydes M, Gelderblom H, / et al.: class="a-plus-plus">Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. / J Clin Oncol 2013, class="a-plus-plus">31:2303-312. class="external" href="http://dx.doi.org/10.1200/JCO.2012.43.8598" target="_blank" title="It opens in new window">CrossRef
10. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A: class="a-plus-plus">Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. / Pediatr Blood Cancer 2006, class="a-plus-plus">47:22-9. class="external" href="http://dx.doi.org/10.1002/pbc.20820" target="_blank" title="It opens in new window">CrossRef
11. Bleyer A, O'Leary M, Barr R, Ries L: / Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-000. Bethesda, MD: National Cancer Institute; 2006. No. 06-767
12. Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM: class="a-plus-plus">Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. / Int J Cancer 2009, class="a-plus-plus">125:426-31. class="external" href="http://dx.doi.org/10.1002/ijc.24376" target="_blank" title="It opens in new window">CrossRef
13. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS: class="a-plus-plus">Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the children’s oncology group soft tissue sarcoma committee. / Cancer 2012, class="a-plus-plus">118:1130-137. class="external" href="http://dx.doi.org/10.1002/cncr.26358" target="_blank" title="It opens in new window">CrossRef
14. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, Balladelli A, Pratelli L, Bacci G: class="a-plus-plus">Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. / J Chemother 2009, class="a-plus-plus">21:205-10.
15. Gao B, Klumpen HJ, Gurney H: class="a-plus-plus">Dose calculation of anticancer drugs. / Expert Opin Drug Metab Toxicol 2008, class="a-plus-plus">4:1307-319. class="external" href="http://dx.doi.org/10.1517/17425255.4.10.1307" target="_blank" title="It opens in new window">CrossRef
16. Canal P, Chatelut E, Guichard S: class="a-plus-plus">Practical treatment guide for dose individualisation in cancer chemotherapy. / Drugs 1998, class="a-plus-plus">56:1019-038. class="external" href="http://dx.doi.org/10.2165/00003495-199856060-00006" target="_blank" title="It opens in new window">CrossRef
17. Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O: class="a-plus-plus">Amputation and adriamycin in primary osteosarcoma. / N Engl J Med 1974, class="a-plus-plus">291:998-000. class="external" href="http://dx.doi.org/10.1056/NEJM197411072911903" target="_blank" title="It opens in new window">CrossRef
18. Gurney H: class="a-plus-plus">I don’t underdose my patients…do I? / Lancet Oncol 2005, class="a-plus-plus">6:637-38. class="external" href="http://dx.doi.org/10.1016/S1470-2045(05)70296-5" target="_blank" title="It opens in new window">CrossRef
19. Gurney H: class="a-plus-plus">Developing a new framework for dose calculation. / J Clin Oncol 2006, class="a-plus-plus">24:1489-490. class="external" href="http://dx.doi.org/10.1200/JCO.2005.05.1607" target="_blank" title="It opens in new window">CrossRef
20. Gurney H: class="a-plus-plus">Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. / J Clin Oncol 1996, class="a-plus-plus">14:2590-611.
21. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A: class="a-plus-plus">Role of body surface area in dosing of investigational anticancer agents in adults, 1991-001. / J Natl Cancer Inst 2002, class="a-plus-plus">94:1883-888. class="external" href="http://dx.doi.org/10.1093/jnci/94.24.1883" target="_blank" title="It opens in new window">CrossRef
22. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, / et al.: class="a-plus-plus">Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: a children’s oncology group study. / J Clin Oncol 2009, class="a-plus-plus">27:2536-541. class="external" href="http://dx.doi.org/10.1200/JCO.2008.19.1478" target="_blank" title="It opens in new window">CrossRef
23. Womer RB, Daller RT, Fenton JG, Miser JS: class="a-plus-plus">Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. / Eur J Cancer 2000, class="a-plus-plus">36:87-4. class="external" href="http://dx.doi.org/10.1016/S0959-8049(99)00236-1" target="_blank" title="It opens in new window">CrossRef
24. Womer R, West D, Krailo M, Dickman P, Pawel B: class="a-plus-plus">Randomized comparison of every-two-week v. Every-three-week chemotherapy in ewing sarcoma family tumors (ESFT). / J Clin Oncol 2008,class="a-plus-plus">26(supp)class="a-plus-plus">:554s.
25. Newell DR: class="a-plus-plus">Getting the right dose in cancer chemotherapy–time to stop using surface area? / Br J Cancer 2002, class="a-plus-plus">86:1207-208. class="external" href="http://dx.doi.org/10.1038/sj.bjc.6600226" target="_blank" title="It opens in new window">CrossRef
26. Gurney H: class="a-plus-plus">How to calculate the dose of chemotherapy. / Br J Cancer 2002, class="a-plus-plus">86:1297-302. class="external" href="http://dx.doi.org/10.1038/sj.bjc.6600139" target="_blank" title="It opens in new window">CrossRef
27. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B: class="a-plus-plus">The distinctive biology of cancer in adolescents and young adults. / Nat Rev Cancer 2008, class="a-plus-plus">8:288-98. class="external" href="http://dx.doi.org/10.1038/nrc2349" target="_blank" title="It opens in new window">CrossRef
28. Veal GJ, Hartford CM, Stewart CF: class="a-plus-plus">Clinical pharmacology in the adolescent oncology patient. / J Clin Oncol 2010, class="a-plus-plus">28:4790-799. class="external" href="http://dx.doi.org/10.1200/JCO.2010.28.3473" target="_blank" title="It opens in new window">CrossRef
29. Smith SD, Rosen D, Trueworthy RC, Lowman JT: class="a-plus-plus">A reliable method for evaluating drug compliance in children with cancer. / Cancer 1979, class="a-plus-plus">43:169-73. class="external" href="http://dx.doi.org/10.1002/1097-0142(197901)43:1<169::AID-CNCR2820430125>3.0.CO;2-F" target="_blank" title="It opens in new window">CrossRef
30. Mitchell AE, Scarcella DL, Rigutto GL, Thursfield VJ, Giles GG, Sexton M, Ashley DM: class="a-plus-plus">Cancer in adolescents and young adults: treatment and outcome in Victoria. / Med J Aust 2004, class="a-plus-plus">180:59-2.
31. Bleyer A, Budd T, Montello M: class="a-plus-plus">Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. / Cancer 2006, class="a-plus-plus">107:1645-655. class="external" href="http://dx.doi.org/10.1002/cncr.22102" target="_blank" title="It opens in new window">CrossRef
32. Burke ME, Albritton K, Marina N: class="a-plus-plus">Challenges in the recruitment of adolescents and young adults to cancer clinical trials. / Cancer 2007, class="a-plus-plus">110:2385-393. class="external" href="http://dx.doi.org/10.1002/cncr.23060" target="_blank" title="It opens in new window">CrossRef
33. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A: class="a-plus-plus">Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the german hodgkin study group. / J Clin Oncol 2005, class="a-plus-plus">23:8003-011. class="external" href="http://dx.doi.org/10.1200/JCO.2005.205.60" target="_blank" title="It opens in new window">CrossRef
34. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, / et al.: class="a-plus-plus">Scandinavian sarcoma group osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. / Eur J Cancer 2003, class="a-plus-plus">39:488-94. class="external" href="http://dx.doi.org/10.1016/S0959-8049(02)00747-5" target="_blank" title="It opens in new window">CrossRef
35. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, / et al.: class="a-plus-plus">Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. / J Clin Oncol 2002, class="a-plus-plus">20:776-90. class="external" href="http://dx.doi.org/10.1200/JCO.20.3.776" target="_blank" title="It opens in new window">CrossRef
36. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F: class="a-plus-plus">Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. / Acta Oncol 2006, class="a-plus-plus">45:469-75. class="external" href="http://dx.doi.org/10.1080/02841860500519760" target="_blank" title="It opens in new window">CrossRef
37. Gehan EA, Nesbit ME Jr, Burgert EO Jr, Viettit J, Tefft M, Perez CA, Kissane J, Hempel C: class="a-plus-plus">Prognostic factors in children with Ewing’s sarcoma. / Natl Cancer Inst Monogr 1981, class="a-plus-plus">56:273-78.
38. Thomas DM, Albritton KH, Ferrari A: class="a-plus-plus">Adolescent and young adult oncology: an emerging field. / J Clin Oncol 2010, class="a-plus-plus">28:4781-782. class="external" href="http://dx.doi.org/10.1200/JCO.2010.30.5128" target="_blank" title="It opens in new window">CrossRef
39. Loomba-Albrecht LA, Styne DM: class="a-plus-plus">Effect of puberty on body composition. / Curr Opin Endocrinol Diabetes Obes 2009, class="a-plus-plus">16:10-5. class="external" href="http://dx.doi.org/10.1097/MED.0b013e328320d54c" target="_blank" title="It opens in new window">CrossRef
40. Cheymol G: class="a-plus-plus">Effects of obesity on pharmacokinetics implications for drug therapy. / Clin Pharmacokinet 2000, class="a-plus-plus">39:215-31. class="external" href="http://dx.doi.org/10.2165/00003088-200039030-00004" target="_blank" title="It opens in new window">CrossRef
41. Hijiya N, Panetta JC, Zhou Y, Kyzer EP, Howard SC, Jeha S, Razzouk BI, Ribeiro RC, Rubnitz JE, Hudson MM, / et al.: class="a-plus-plus">Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. / Blood 2006, class="a-plus-plus">108:3997-002. class="external" href="http://dx.doi.org/10.1182/blood-2006-05-024414" target="_blank" title="It opens in new window">CrossRef
42. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM: class="a-plus-plus">Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? / Eur J Cancer 2011, class="a-plus-plus">47:2431-445. class="external" href="http://dx.doi.org/10.1016/j.ejca.2011.05.030" target="_blank" title="It opens in new window">CrossRef
43. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD: class="a-plus-plus">Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. / Cancer Chemother Pharmacol 1995, class="a-plus-plus">36:473-76. class="external" href="http://dx.doi.org/10.1007/BF00685796" target="_blank" title="It opens in new window">CrossRef
44. Rodvold KA, Rushing DA, Tewksbury DA: class="a-plus-plus">Doxorubicin clearance in the obese. / J Clin Oncol 1988, class="a-plus-plus">6:1321-327. - 作者单位：Jeremy Lewin (1)
Samantha Wieringa (2)
Marnie Collins (1)
Jayesh Desai (1)
Lisa Orme (1)
Senthil Lingaratnam (2)
David M Thomas (1)
1. Sarcoma Service, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne, VIC, 8006, Australia
2. Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia - ISSN：2045-3329
文摘
Background Data suggests that males experience less toxicity and poorer survival than females treated for Ewing’s sarcoma. We instituted an intra-patient dose escalation (DE) policy with Vincristine/Doxorubicin/Cyclophosphamide (VDC) alternating with Ifosfamide/Etoposide (IE) based on hematological nadirs and report its feasibility and safety. Methods A retrospective review of adherence to DE guidelines and toxicities was conducted for patients who received DE with VDC/IE over 3?years at a single cancer center. Absolute neutrophil counts (ANC) was collected on days 8, 12 and 15 for cycles 1-. DE of 10%/cycle was applied if ANC-gt;-.5×109/L and platelet-gt;-00×109/L on all blood results. The primary endpoint was the proportion of patients who received appropriate DE. The secondary endpoint was to assess morbidity, changes in hematologic nadirs between gender and age and a comparison with a prior cohort of ESFT patients who did not receive DE. Gender comparisons were assessed via independent 2-sample t-tests assuming unequal variances. Within cycle changes in hematologic nadirs were assessed using repeated measures ANOVA. Relapse free survival and overall survival (OS) curves were estimated using the Kaplan-Meier method. Results 23 patients were identified (mean age: 27; range 17-4). 91 decisions for DE were made (1 decision excluded because of progressive disease) with 90% concordance with guidelines. No adverse outcomes occurred as a result of the inappropriate escalation. Grade 3/4 febrile neutropenia (FN) during VDC and IE was 26.1% (6/23 patients) and 17.4% respectively with no difference for those who were DE. Males were less neutropenic after C1 and C3 of VDC compared to females (P-value C1--.003; C3--.005). VDC was associated with greater neutropenia on day 8 whereas IE had greater neutropenia on day 12 (P-value <0.001). During VDC, a non statistical difference in neutropenia was seen for individuals aged 15-5 (n--3) compared with older individuals (P-value--.09). OS comparison for those with localized disease with a prior cohort who were not DE showed similar outcomes (P-value--.37). Conclusions DE is deliverable without increased adverse outcomes. Males have less myelosuppression during VDC, and should be especially considered for DE.